AdventHealth Cancer Institute’s (AHCI) Tarek Mekhail, MD, and Michael McPhee, MD, recently published a partner spotlight article in the Journal of Clinical Pathways highlighting the establishment of a Cutaneous Oncology Consortium (COC) in 2020 designed to improve the outcomes of Central Florida patients with malignant melanoma.
The Food and Drug Administration’s approval of ipilimumab for the treatment of metastatic melanoma in 2011 helped to revolutionize the care of metastatic melanoma patients. New treatments have continued to emerge over the past decade, advancing the care delivery model. Because most melanomas are treated in the community setting, AHCI decided to engage with these providers to ensure a more seamless approach to care and specialist referrals for patients with systemic disease.
As a result, the COC is comprised of physician members representing all specialties who share expertise in the care of patients with malignant melanoma. Its foundation has been a dedicated Multidisciplinary Melanoma Tumor Board (MMTB) that began in January 2021. The MMTB provides second opinion reviews on pathology, prospective treatment plans, clinical trial screenings, and navigation support for patients.
Each COC meeting includes discussion and evaluation of the latest evidence using a hierarchy of efficacy, toxicity and cost. In addition, in 2018, AdventHealth implemented Elsevier’s ClinicalPath (formerly Via Oncology) evidence-based, multidisciplinary oncology pathways which are developed by leading oncologists throughout the country. The MMTB users both of these resources to guide evidence-based decision-making for melanoma patients in an effort to improve outcomes.
Recently, the MMTB discussed a patient with cutaneous squamous cell carcinoma, with locally advanced unresectable disease. Because this was a presentation not often seen at AHCI, the MMTB consulted the pathways, which indicated that treatment with neoadjuvant cemiplimab was supported by the literature.
Future plans for the COC include further enhancing the referral process for melanoma patients to ensure more seamless continuity of care.
Link to published article: https://www.hmpgloballearningnetwork.com/site/jcp/sponsored/leveraging-evidence-based-oncology-pathways-inform-multidisciplinary-tumor-board
12 items. To interact with these items, press Control-Option-Shift-Right Arrow. These items are in a slider. To advance slider forward, press Shift-Command-Right Arrow. To advance slider backward, press Shift-Command-Left Arrow.
News
Respiratory Virus Testing Guidance for Flu Season
Physician leaders from AdventHealth’s emergency department, infectious disease, inpatient, pediatrics and pharmacy teams all collaborated to develop a respiratory virus testing algorithm to assist...
News
AdventHealth Celebration Introduces New Intraoperative Molecular Imaging Process to Improve Accuracy of Lung Cancer Surgery
Thoracic surgeon Colleen Gaughan, MD, and her team at AdventHealth Celebration, recently became one of the first in the country to incorporate targeted imaging agent Cytalux (pafolacianine) as part of...
News
An incredible journey through two open heart surgeries at AdventHealth
On the newest Inspiring Wholeness podcast, Obie Diaz, local morning radio show host, shares how a routine physical eventually led to two open heart surgeries.
News
Using Genomics and AI to Improve Breast Cancer Risk Assessment and Early Detection
AdventHealth recently began piloting a new Genomics Risk Assessment for Cancer and Early Detection (GRACE) program that combines the use of digital mammography, artificial intelligence (AI) technology...
News
New Research Published in New England Journal of Medicine Finds That Adjuvant Pembrolizumab Extends Disease-Free Survival in Muscle-Invasive Urothelial Carcinoma
AdventHealth Clinical Research Unit (CRU) Executive Director and Medical Director of Genitourinary Oncology Guru Sonpavde, MD, co-authored an article on the AMBASSADOR Phase III clinical trial results...
News
AdventHealth to Implement Research to Combat Antibiotic Resistance in Kids
AdventHealth is accelerating the use of research-backed best practices for treating pediatric respiratory infections to combat antibiotic resistance and improve patient outcomes.
News
New treatment for AFib patients shows less tissue damage and improved outcomes, offered first at AdventHealth
A promising new treatment for AFib patients called Pulse Field Ablation is first offered in Central Florida at AdventHealth and shows less damage to tissue.
News
AdventHealth Physician Team Performs Central Florida’s First Immediate Breast Neurotization After Nipple-sparing Mastectomy
Plastic and Reconstructive Microsurgeon Sabrina Pavri, MD, and Breast Surgeon Devina McCray, MD, recently began offering immediate neurotization after breast reconstruction, a new surgical technique...
News
Bridging the Gap: Elevating Hispanic Leaders in Central Florida
Explore the importance of Hispanic representation in our community in this episode of the Inspiring Wholeness podcast.
News
AdventHealth for Women Launches Central Florida’s First Comprehensive Uterine Fibroid Program to Enhance Patient Care
Under the leadership of gynecologist and gynecological surgeon Omar Zwain, MD, AdventHealth for Women opened its new, multidisciplinary Comprehensive Fibroid Program at AdventHealth Winter Park in...
News
AdventHealth for Children Recruiting Patients with Fabry Disease for Phase III PERIDOT Clinical Trial Evaluating a Potential New Treatment Option
Under the leadership of Medical Director of Genomics and Personalized Health Majed Dasouki, MD, AdventHealth for Children is recruiting patients for a new Phase III clinical trial to evaluate the...
News
AdventHealth Celebration is Among First in the State to Offer Non-invasive Histotripsy Treatment for Unresectable Liver Tumors
Hepato-pancreato-biliary (HPB) surgeon Andrew Guzowski, MD, performed AdventHealth’s first liver histotripsy, a non-invasive treatment for certain patients with unresectable liver tumors.